Evidence mapPaperPMID 40087882Full record

ReviewImmunological reviews2025

Innate Immunity and Asthma Exacerbations: Insights From Human Models.

Jehan Alladina, Benjamin D Medoff, Josalyn L Cho

Abstract readReview
In one paragraph

Review in Immunological reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jehan AlladinaDivision of Pulmonary and Critical Care Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Benjamin D MedoffDivision of Pulmonary and Critical Care Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0002-2558-0449
Josalyn L ChoDivision of Pulmonary, Critical Care and Occupational Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA.

Funding

Pulmonary Toxicology FacilityP30ES005605 · UNIVERSITY OF IOWA · 1990 to 2025
$8.8M
Mapping Airway Epithelial Cell-Immune Cell Interactions in Lung Health and DiseaseU01HL175384 · MASSACHUSETTS GENERAL HOSPITAL · 2025 to 2025
$781k
The Impact of Soluble ST2 on Lung Injury Onset and ResolutionK08HL173572 · MASSACHUSETTS GENERAL HOSPITAL · 2025 to 2025
$171k
National Institute of Allergy and Infectious Diseases UH2 AI44434NHLBI NIH HHS K08 HL173572NHLBI NIH HHS U01 HL175384NIAID NIH HHS R21 AI176580NIEHS NIH HHS P30 ES005605
6 · The paper itself

Abstract

Asthma is a common chronic respiratory disease characterized by the presence of airway inflammation, airway hyperresponsiveness, and mucus hypersecretion. Repeated asthma exacerbations can lead to progressive airway remodeling and irreversible airflow obstruction. Thus, understanding and preventing asthma exacerbations are of paramount importance. Although multiple endotypes exist, asthma is most often driven by type 2 airway inflammation. New therapies that target specific type 2 mediators have been shown to reduce the frequency of asthma exacerbations but are incompletely effective in a significant number of asthmatics. Furthermore, it remains unknown whether current treatments lead to sustained changes in the airway or if targeting additional pathways may be necessary to achieve asthma remission. Activation of innate immunity is the initial event in the inflammatory sequence that occurs during an asthma exacerbation. However, there continue to be critical gaps in our understanding of the innate immune response to asthma exacerbating factors. In this review, we summarize the current understanding of the role of innate immunity in asthma exacerbations and the methods used to study them. We also identify potential novel therapeutic targets for asthma and future areas for investigation.

Indexed as

AsthmaImmunity, InnateAirway RemodelingAnimalsDisease ProgressionHumansasthma exacerbationsinnate immunitysegmental allergen challengetype 2 inflammation

Identifiers

PMID40087882
PMCPMC11922041

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.